- Email: [email protected]
5028308 Apparatus for the electrophoretic separation of highmolecular DNA in gel
PATENT ABSTRACTS
463
predicted amino acid sequence of human transferrin is disclosed as well. The cDNA-bearing recombinant plasmid was selected from a human recombinant clone bank constructed in the plasmid pKT218, a derivative of pBR322. Also disclosed are proposed methods and compositions for constructing a recombinant expression vector whereby one may obtain expression of the recombinant human transferrin protein.
PS In a preferred embodiment, the DNA sequence encodes basic fibroblast growth factor (bFGF).
5026837
David R Beritashvili, Lev V Karklit, Konstantin Skryabin, Evgeny N Tverdokhlebov, Andrei I Poletaev, Mo.~ow, Union Of Soviet Socialist Republics
DNA PROBE WHICH REVEALS A HYPERVARIABLE REGION ON HUMAN CHROMOSOME 16 Michae Litt, Linda L Burton assigned to The State of Oregon acting by and through the State Board of Higher Education on behalf of Oregon Health Sciences University A DNA probe p79-2-23 is homologous to at least a portion of a hypervariable DNA region located on chromosome 16q22 right arrowq24 in the human genome. The DNA region displays a restriction fragment length polymorphism when digested with certain restriction endonucleases. Unrelated individuals display unique fragment patterns on Southern blots probed with p79-223. The probe can be used to produce a genetic fingerprint for establishing human identity, determining engraftment of bone marrow transplants, determining parentage, and otherwise mapping genes.
5026839 DNA ENCODING A BASIC FIBROBLAST GROWTH FACTOR David Moscatelli, Daniel B Rifkin, Andrea Sommer assigned to Synergen lnc; New York Universi An isolated DNA sequence encoding an angiogenic factor protein consisting of a singlepolypeptide-chain protein having at least one active site possessing mitotic and chemotactic activity and the ability to stimulate protease synthesis, wherein said protein consists of the amino acid sequence: See Patent for Chemical Structure
5028308 APPARATUS FOR THE ELECTROPHORETIC SEPARATION OF HIGHMOLECULAR DNAIN GEL
An apparatus has an electrophoretic chamber in which groups of electrodes are positioned along sides of an equilateral quadrangle. Electrodes within each group are positioned in equally spaced relation to one another and are connected to a power supply via a switching circuit.
5028420 MUTEINS OF TUMOR FACTOR
NECROSIS
Tsuki Masegi, Satoshi Nakamura, Kazuo Kitai, Masami Fukuoka, Kenji Yone, Arata Kato, Jun Suzuki, Noriyuki Tsunekawa, Yataro Ichikawa, Hino, Japan assigned to Teijin Limited A novel physiologically active polypeptide having antitumor activity obtained by improving human tumor necrosis factor (TNF). The amino acid sequence of the polypeptide essentially corresponds to that of human tumor necrosis factor, except that ten amino acids Nos. l to l0 are deleted and (Met)n-Arg-Lys-Arg are added to the amino (NH2)-terminus, where n is 0 or I. Other amino acid modifications can also be made to the polypeptide while retaining high antitumor activity. The novel polypeptide has less side effects that the natural-type TNF, particularly with respect to cytotoxicity. A a DNA fragment encoding the polypeptide, a recombinant plasmid containing the DNA fragment, a recombinant microorganism cell transformed with the plasmid, a method of producing a novel physiologically active polypeptide using the microorganism cell, and a pharmaceutical composition comprising the polypeptide as an active ingredient are also provided.
463
predicted amino acid sequence of human transferrin is disclosed as well. The cDNA-bearing recombinant plasmid was selected from a human recombinant clone bank constructed in the plasmid pKT218, a derivative of pBR322. Also disclosed are proposed methods and compositions for constructing a recombinant expression vector whereby one may obtain expression of the recombinant human transferrin protein.
PS In a preferred embodiment, the DNA sequence encodes basic fibroblast growth factor (bFGF).
5026837
David R Beritashvili, Lev V Karklit, Konstantin Skryabin, Evgeny N Tverdokhlebov, Andrei I Poletaev, Mo.~ow, Union Of Soviet Socialist Republics
DNA PROBE WHICH REVEALS A HYPERVARIABLE REGION ON HUMAN CHROMOSOME 16 Michae Litt, Linda L Burton assigned to The State of Oregon acting by and through the State Board of Higher Education on behalf of Oregon Health Sciences University A DNA probe p79-2-23 is homologous to at least a portion of a hypervariable DNA region located on chromosome 16q22 right arrowq24 in the human genome. The DNA region displays a restriction fragment length polymorphism when digested with certain restriction endonucleases. Unrelated individuals display unique fragment patterns on Southern blots probed with p79-223. The probe can be used to produce a genetic fingerprint for establishing human identity, determining engraftment of bone marrow transplants, determining parentage, and otherwise mapping genes.
5026839 DNA ENCODING A BASIC FIBROBLAST GROWTH FACTOR David Moscatelli, Daniel B Rifkin, Andrea Sommer assigned to Synergen lnc; New York Universi An isolated DNA sequence encoding an angiogenic factor protein consisting of a singlepolypeptide-chain protein having at least one active site possessing mitotic and chemotactic activity and the ability to stimulate protease synthesis, wherein said protein consists of the amino acid sequence: See Patent for Chemical Structure
5028308 APPARATUS FOR THE ELECTROPHORETIC SEPARATION OF HIGHMOLECULAR DNAIN GEL
An apparatus has an electrophoretic chamber in which groups of electrodes are positioned along sides of an equilateral quadrangle. Electrodes within each group are positioned in equally spaced relation to one another and are connected to a power supply via a switching circuit.
5028420 MUTEINS OF TUMOR FACTOR
NECROSIS
Tsuki Masegi, Satoshi Nakamura, Kazuo Kitai, Masami Fukuoka, Kenji Yone, Arata Kato, Jun Suzuki, Noriyuki Tsunekawa, Yataro Ichikawa, Hino, Japan assigned to Teijin Limited A novel physiologically active polypeptide having antitumor activity obtained by improving human tumor necrosis factor (TNF). The amino acid sequence of the polypeptide essentially corresponds to that of human tumor necrosis factor, except that ten amino acids Nos. l to l0 are deleted and (Met)n-Arg-Lys-Arg are added to the amino (NH2)-terminus, where n is 0 or I. Other amino acid modifications can also be made to the polypeptide while retaining high antitumor activity. The novel polypeptide has less side effects that the natural-type TNF, particularly with respect to cytotoxicity. A a DNA fragment encoding the polypeptide, a recombinant plasmid containing the DNA fragment, a recombinant microorganism cell transformed with the plasmid, a method of producing a novel physiologically active polypeptide using the microorganism cell, and a pharmaceutical composition comprising the polypeptide as an active ingredient are also provided.